Additional file 2 of A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping

Wen, Q

, Kim, C, Hamilton, P and Zhang, S (2016). Additional file 2 of A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping. [Dataset]. Figshare. https://doi.org/10.6084/m9.figshare.c.3624356_D2.v1

Copy

Significant drugs returned with the k=50 HDACi gene signature. The list of significant drugs returned from sscMap using the k=50 HDACi gene signature from the "simulated experiment". All 7 known HDAC inhibitors were pulled out, but together with many other drugs, which may or may not related to HDAC inhibition. The main biological theme (HDAC inhibition) could potentially be weakned or even masked due to the co-existence of many other drugs.

Keywords

Connectivity mapping, Differentially expressed genes, Gene signature progression, Disease inhibitory compounds, Lung cancer, Breast cancer

Item Type	Dataset
Capture method	Unknown
Date	11 May 2016
Language(s) of written materials	English
Creator(s)	Wen, Q , Kim, C, Hamilton, P and Zhang, S
LSHTM Faculty/Department	Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Participating Institutions	Queen’s University Belfast, Belfast, United Kingdom, STFC Daresbury Laboratory, Daresbury, Warrington, United Kingdom, University of Ulster, Altnagelvin Hospital campus, Derry/Londonderry, United Kingdom
Funders	Project Funder Grant Number Funder URI Doctoral Training Grant Engineering and Physical Sciences Research Council UNSPECIFIED http://dx.doi.org/10.13039/501100000266 UNSPECIFIED Biotechnology and Biological Sciences Research Council BB/I009051/1 http://dx.doi.org/10.13039/501100000268 People Programme (Marie Curie Actions) Seventh Framework Programme UNSPECIFIED http://dx.doi.org/10.13039/100011102
Date Deposited	04 Jan 2024 17:09
Last Modified	04 Jan 2024 17:09
Publisher	Figshare